Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China-Reference-Cited by-同舟云学术

Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Published:2019-01 Issue: Volume:127 Page:84-89
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gu Xiaohua,Zhang Qiang,Chu Yun-Bo,Zhao Yi-Yang,Zhang Yan-Jun,Kuo David,Su Betty,Wu Bin^ORCID

Funder

Boehringer Ingelheim

Fourth Round of the Three-year Action Plan on Public Health Discipline and Talent Program

Shanghai Health and Family Planning Commission

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J. Clin.,2015

2. Cancer statistics in China, 2015;Chen;CA Cancer J. Clin.,2016

3. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC);Felip;Ann. Oncol.,2005

4. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data;William;Chest,2009

5. The guideline for diagnosis and treatment of Chinese patients with sensitizing EGFR mutation or ALK fusion gene-positive non-small cell lung cancer (2015 Version);Zhonghua Zhong Liu Za Zhi,2015

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland;Frontiers in Pharmacology;2024-07-12

2. Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients;Frontiers in Immunology;2024-04-22

3. The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma;Pharmacogenomics;2024-04-12

4. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

5. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma;PLOS ONE;2024-03-04